Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Ferrero

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Journal of Chemotherapy (Florence, Italy)|June 2, 2006
Home infusions of biphosphonate in cancer patients: a prospective studyA Italiano, C Ciais, E Chamorey, et al.
Anti-Cancer Drugs|June 23, 1999
Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell linesK Ilc, J M Ferrero, J L Fischel, et al.
Bulletin Du Cancer|March 1, 1995
[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma]J M Ferrero, X Pivot, M Namer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-upJ M Ferrero, A Ramaioli, R Largillier, et al.
Oncology|April 18, 2008
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapyR Largillier, B Valenza, J-M Ferrero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)A Awada, I N Bondarenko, J Bonneterre, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
Age-related difference in tamoxifen dispositionF Peyrade, M Frenay, M C Etienne, et al.
Public Health Genomics|April 11, 2013
Breast cancer patients' views on the use of genomic testing to guide decisions about their postoperative chemotherapyV Seror, P Marino, F Bertucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patientsS Oudard, E Banu, F Scotte, et al.
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|January 1, 1992
[Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies]P Carde, C Chastang, E Goncalves, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Journal of Chemotherapy (Florence, Italy)|June 2, 2006
Home infusions of biphosphonate in cancer patients: a prospective studyA Italiano, C Ciais, E Chamorey, et al.
Anti-Cancer Drugs|June 23, 1999
Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell linesK Ilc, J M Ferrero, J L Fischel, et al.
Bulletin Du Cancer|March 1, 1995
[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma]J M Ferrero, X Pivot, M Namer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-upJ M Ferrero, A Ramaioli, R Largillier, et al.
Oncology|April 18, 2008
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapyR Largillier, B Valenza, J-M Ferrero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)A Awada, I N Bondarenko, J Bonneterre, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
Age-related difference in tamoxifen dispositionF Peyrade, M Frenay, M C Etienne, et al.
Public Health Genomics|April 11, 2013
Breast cancer patients' views on the use of genomic testing to guide decisions about their postoperative chemotherapyV Seror, P Marino, F Bertucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patientsS Oudard, E Banu, F Scotte, et al.
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|January 1, 1992
[Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies]P Carde, C Chastang, E Goncalves, et al.
Pageof 8